MYELODYSPLASTIC SYNDROMES

This study tests an experimental drug called DISC-0974 in 150 adults with myelofibrosis or myelodysplastic syndrome who also have anemia. The goal is to see if the drug can reduce the need for blood transfusions and raise hemoglobin levels safely. Participants receive the drug by…

This study tests a new automated method (CliniMACS Prodigy) to select specific stem cells for transplant in people with blood cancers like leukemia or lymphoma. The goal is to lower the risk of graft-versus-host disease, a serious complication where donor cells attack the patient…

This early-phase study tests whether adding the drug momelotinib to standard treatment (azacitidine) can better control certain rare blood cancers (MDS/MPN overlap and chronic neutrophilic leukemia). About 18 adults will take the combination for up to 24 months. The goal is to im…

This study tests a personalized cell therapy called Orca-T for 80 adults with acute myeloid leukemia or myelodysplastic syndrome. Participants receive a stem cell transplant with specially processed donor cells designed to reduce complications like graft-versus-host disease. The …

This early-stage study tests a new drug called MGD024 in about 130 adults with certain blood cancers (like leukemia or lymphoma) that did not get better with standard treatments or came back. The main goal is to find a safe dose and understand side effects. Participants receive t…

This study looks at how the cancer drug ASTX727 works in people with moderate or severe liver problems. It includes 27 adults with certain blood cancers or solid tumors. The goal is to understand how the liver affects the drug's safety and processing in the body.

This study tests a drug called olutasidenib in 15 people with certain blood disorders (CCUS, lower-risk MDS, or CMML) that have an IDH1 gene mutation. The goal is to see if the drug can control the disease and improve blood counts. Researchers will also monitor for side effects.

This study tests a new experimental drug called EP0042, alone or with other cancer treatments, in people with advanced blood cancers like acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelodysplastic syndromes (MDS). The goal is to find a dose that is …

This early-phase study tests a specially engineered donor stem cell product called Orca-Q in people with blood cancers like leukemia or myelodysplastic syndromes who need a stem cell transplant. The goal is to see if it is safe and helps the body accept the new cells while reduci…

This study tests an experimental drug called elritercept in adults with a bone marrow disorder called myelodysplastic syndromes (MDS) who need regular red blood cell transfusions. The main goal is to see if the drug can help patients go at least 8 weeks without needing a transfus…

This study tests if using two different donors (a half-matched family donor and a cord blood unit) for a stem cell transplant can help people with certain blood cancers live longer without the cancer coming back. About 36 adults with leukemia or related disorders will receive thi…

This early-phase study tests whether specially trained natural killer (NK) cells can safely prevent leukemia from returning after a stem cell transplant. About 15 adults with high-risk acute myeloid leukemia or related blood cancers will receive an infusion of these cells plus a …

This early-phase study tests a new type of immune cell (CIML NK cells) combined with a low-dose drug (IL-2) in people whose leukemia or related blood cancers have returned after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into rem…

This early-stage study tests a new drug, SX-682, alone or with another drug (decitabine) in people with myelodysplastic syndrome (MDS), a bone marrow disorder. The main goal is to find a safe dose and check for side effects. About 151 adults with MDS who have not responded to pri…

This study tests whether a new way of giving three drugs (ATG, tacrolimus, and methotrexate) can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers like leukemia. About 29 adults aged 18-60 who have a matched dono…

This study tests how well umbilical cord blood stem cells from unrelated donors restore blood cell counts in people with serious blood cancers, immune deficiencies, or genetic disorders. About 30 participants will receive a transplant, and researchers will track engraftment succe…

This early-phase study tests a new oral drug, GLB-001, in about 48 adults whose acute myeloid leukemia or high-risk myelodysplastic syndromes have returned or not responded to standard therapy. The main goals are to find a safe dose and check for side effects, while also looking …

This early-phase study is testing whether adding the drug venetoclax to standard chemotherapy can safely treat adults with newly diagnosed acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). About 99 participants will receive different doses of venetoclax alo…

This study tests whether adding high-dose vitamin C to a standard chemotherapy drug (azacitidine) can improve outcomes for adults with myelodysplastic syndrome (MDS), a bone marrow disorder. About 38 participants with higher-risk MDS will receive both treatments intravenously. Th…

This study tests a stem cell transplant that removes certain immune cells to lower the risk of graft-versus-host disease (GVHD) and reduce the need for long-term immune-suppressing drugs. It is for people with inherited bone marrow failure disorders like Fanconi anemia. The goal …

This study tests an experimental drug called CTX-712 in adults whose acute myeloid leukemia or myelodysplastic syndromes have returned or not responded to prior treatments. The goal is to find the safest dose and see if the drug can shrink or control the cancer. About 225 partici…

This study tests whether giving extra natural killer (NK) cells from a donor can safely help prevent leukemia or MDS from coming back after a stem cell transplant. About 10 adults with acute myeloid leukemia or myelodysplastic syndromes who don't have a fully matched donor will r…

This early-phase study tests a new treatment for adults with acute myeloid leukemia or myelodysplastic syndrome who still have measurable disease after standard therapy. The treatment uses the patient's own blood cells that are specially armed with a bispecific antibody to target…

This study tests an experimental drug called elritercept (KER-050) in about 160 adults with a bone marrow disorder (MDS) that causes low red blood cells and anemia. The main goal is to see if the drug is safe and well-tolerated at different doses, and whether it can help the body…

This early-phase study tests a new stem cell transplant method for people with aggressive or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially engineered donor cells to reduce the risk of graft-versus-host disease, aiming t…

This study tests a drug called momelotinib in 80 adults with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if the drug can help them go without red blood cell transfusions for at least 12 weeks. The trial has two parts: first to find the best dose, …

This study tests a drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood disorders. The goal is to find the best dose and see if it can control the disease. Participants take the drug twice daily for up to 8 years, with regular c…

This early-stage study tests a new treatment called MNV-201 for people with low-risk myelodysplastic syndrome (MDS), a bone marrow disorder that causes low blood counts. The therapy uses the patient's own blood stem cells enriched with mitochondria from donated placentas to try t…

This study tests a new drug called AND017 for anemia in people with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS). The goal is to see if the drug can raise hemoglobin levels or reduce the need for blood transfusions. About 63 participants will r…

This study looks at how the oral cancer drug ASTX727 behaves in people with severe kidney impairment compared to those with normal kidneys. It involves 18 adults with certain blood cancers or solid tumors. The goal is to understand safety and drug levels, not to cure the disease.

This study tests a low-dose weekly schedule of two FDA-approved drugs, decitabine and venetoclax, for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler approach can keep patients on treatment longer with fewer interruptions. About 91 adul…

This early-phase trial tests a new approach for people with advanced blood cancers who are getting a stem cell transplant. Doctors will give patients specially prepared immune cells (regulatory T-cells and conventional T-cells) along with the transplant to help the body accept th…

This early-phase study tests whether giving patients special immune cells (gamma delta T-cells) after a partially matched bone marrow transplant can help kill cancer cells while reducing the risk of graft-versus-host disease. About 38 adults with certain blood cancers or bone mar…

This early-phase trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in people with advanced blood cancers like leukemia. Participants receive a stem cell transplant from a partially matched donor (7 out of 8 HLA marke…

This early-phase study tests an experimental drug called danvatirsen, first alone and then combined with the standard drug venetoclax, in adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to prior treatments. The goal…

This study tests an oral drug (ASTX030) that combines two chemotherapy agents to treat certain blood cancers like myelodysplastic syndromes and acute myeloid leukemia. It aims to see if taking a pill is as effective as getting injections. About 316 adults will participate over ro…

This study tests a new drug called BGB-11417 for people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The goal is to find the safest dose and see if the drug works alone or combined with another cancer medicine. About 260 adults…

This study tests a combination of the drug venetoclax and a chemotherapy-like agent along with an infusion of immune cells from a partially matched donor. It is for people with intermediate- or high-risk myelodysplastic syndromes (MDS) who cannot have a standard stem cell transpl…

This study is testing whether giving two drugs, decitabine and filgrastim, after a stem cell transplant can help prevent leukemia or related blood cancers from coming back in children and young adults. About 37 participants with acute myeloid leukemia, myelodysplastic syndromes, …

This early-phase study tests a new daily pill, BH-30236, for adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior treatments. The trial will first find the safest dose, then test it alone or with another drug (venetoclax…

This study tests a stem cell transplant approach for people with blood cancers like AML and MDS. Participants receive chemotherapy followed by a donor stem cell infusion, plus drugs to prevent graft-versus-host disease. The goal is to improve survival at 100 days and reduce trans…

This study tests whether adding interferon-γ to donor white blood cell infusions can help control acute myeloid leukemia or myelodysplastic syndromes that have returned after a stem cell transplant. About 45 adults will receive the combination and be monitored for at least a year…

This study looks at whether getting a stem cell transplant right away is as good as getting some treatment first and then the transplant for people with higher-risk myelodysplastic syndrome (MDS). About 236 adults who are eligible for a transplant will be randomly assigned to one…

This study tests a combination of four drugs (cladribine, cytarabine, venetoclax, and azacitidine) to see if it can help control higher-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has not responded to standard treatments. About 60 adults age…

This early-stage trial tests whether adding decitabine and venetoclax to a standard stem cell transplant is safe for people with high-risk blood cancers like leukemia. About 20 adults aged 18-75 with a matching donor will take part. The goal is to find the best dose that limits s…

This study tests whether adding venetoclax to the standard chemotherapy given before a stem cell transplant can help prevent relapse in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 patients aged 12 to 60 will be randomly assigne…

This early-phase study tests whether adding an experimental drug (defactinib) to an approved oral treatment (decitabine/cedazuridine) is safe and can work better for people with certain blood cancers like MDS, AML, and CMML. About 12 adults will take the approved drug alone for t…

This study tests an experimental drug called enzomenib in about 600 people with acute leukemia and certain other blood cancers. The goal is to find the safest dose and see if the drug can shrink or control the cancer. Participants must have cancers that came back or did not respo…

This study tests whether giving a drug combination (decitabine and cedazuridine, or DEC-C) early can prevent myelodysplastic syndromes (MDS) from coming back after a stem cell transplant. About 209 adults who have had a transplant and still have tiny amounts of cancer cells (meas…

This study tests whether adding donor cells that have been stripped of certain immune cells (CD45RA-depleted) can help children recover their immune system faster after a stem cell transplant. The goal is to lower the risk of serious viral or fungal infections without increasing …

This early-stage study aims to find a safe and effective dose of a new oral drug, iadademstat, when given alongside a standard chemotherapy drug, azacitidine. It is for adults with higher-risk forms of myelodysplastic syndrome (MDS), a type of bone marrow cancer. The main goal is…

This early-stage study is testing whether specially engineered immune cells (called TSC-100 or TSC-101) can help prevent blood cancers from returning after a stem cell transplant. The study will enroll adults with acute leukemia or myelodysplastic syndromes who are receiving a tr…

This study is testing whether adding an existing drug (ESA) to a newer drug (luspatercept) works better than luspatercept alone for patients with a lower-risk type of MDS, a bone marrow disorder that causes anemia. The trial is for adults whose anemia did not improve or got worse…

This study tests whether luspatercept can help people with lower-risk myelodysplastic syndromes (MDS) need fewer blood transfusions. About 40 adults will receive the drug and be monitored for side effects and transfusion reduction. The goal is to ease the burden of frequent trans…

This study tests whether a tailored exercise program combined with a vitamin-like supplement (called NR) can improve muscle strength, size, and overall fitness in teens and young adults who had a stem cell transplant for leukemia or other blood disorders. About 80 participants, a…

This study looks at whether offering blood transfusions at home for people with advanced blood cancers who are in hospice care can improve their quality of life and mood, and reduce hospital visits near the end of life. About 700 adults with relapsed or hard-to-treat blood cancer…

This study tests whether tranexamic acid (TXA), a medication that prevents blood clots from breaking down, can reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 adults with low platelet counts who are receiving less-intensive…

This study is testing whether giving blood transfusions at home is practical and okay for cancer patients who need transfusions often. About 30 adults with blood cancers or bone marrow problems will receive 1-5 units of blood products at home. Researchers will track how often tra…

This study collects samples like blood, bone marrow, and stool from 1,000 healthy adults to create a reference database. Researchers will compare these samples to those from people with myelodysplastic syndromes (MDS), a group of bone marrow disorders that can lead to blood cance…

This study looks at whether a new whole genome test called ChromoSeq can provide more detailed genetic information for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) than current standard tests. About 325 adults will have their blood or bone marrow tes…

This study collects blood, bone marrow, and tissue samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central bank for researchers to use in future studies. No treatment or direct benefit is offered to participants.

This study collects blood, bone marrow, and other samples from people with non-cancerous blood diseases and their family members. Researchers will analyze DNA and other markers to find genetic causes and factors that affect disease severity and treatment response. The goal is to …

This study gathers health information from 2,000 people receiving stem cell transplants for blood cancers or immune disorders. The goal is to track survival and complications to help improve future treatments and hospital operations. No experimental therapies are given; participa…

This study is testing whether an artificial intelligence tool can help connect cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to ma…

This study looks at whether measuring certain stem cells in the bone marrow can help predict if a patient's myelodysplastic syndrome (MDS) will come back after a stem cell transplant. Researchers will use a special lab test (flow cytometry) to track these stem cells in 163 patien…

This study tests a telehealth program to help older adults (60+) with blood cancers like leukemia talk with their doctors about their care wishes. It aims to reduce anxiety and improve completion of advance directives. About 207 patients and their caregivers will participate remo…

This study aims to learn more about myelodysplastic syndromes (MDS) by following people with the condition and healthy volunteers over many years. Researchers will collect blood, bone marrow, and other samples to better understand how MDS progresses. No new treatments are tested;…

This study looks at people and families with certain inherited gene changes (DDX41) that make them more likely to develop blood cancers like MDS or AML. Researchers will follow participants for up to 10 years to track health outcomes and collect samples. The goal is to better und…

This study looks at how services from a non-profit cancer advocacy organization affect people with blood cancers like leukemia and lymphoma. Researchers will track 400 patients over time to see if the group's programs improve access to care, quality of life, and reduce financial …

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers want to understand why some cases progress and others don't. Up to 10,000 participants will provide extra blood, bone marrow, or cheek swab samples duri…

This study looks at whether certain proteins in the blood (called cytokines) can help predict how well older or sicker patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or chronic myelomonocytic leukemia will do on a gentler type of chemotherapy. Researche…

This study is testing whether a new whole genome test called ChromoSeq can find genetic changes in people with myelodysplastic syndrome (MDS) as well as current standard tests. About 60 adults with suspected or confirmed MDS will provide samples, and doctors will compare the resu…